The role of dendritic cells in MASH: friends or foes?

The role of dendritic cells in MASH: friends or foes?

Dendritic cells (DCs) are major antigen-presenting cells that connect innate and adaptive immunity. Hepatic DCs are less activated and contribute to maintain the tolerogenic environment of the liver under steady state. Several studies indicated DCs in metabolic dysfunction-associated steatohepatitis...

Full description

Bibliographic Details
Main Authors:	Antonio T. Pinto, Veronika Lukacs-Kornek
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Immunology
Subjects:	dendritic cells liver MASH inflammation metabolic dysfunction associated fatty liver disease
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1379225/full

Similar Items

Targeting nuclear receptors for NASH/MASH: From bench to bedside
by: Rohit A. Sinha
Published: (2024-03-01)

Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver diseaseKey points
by: Guillaume Henin, et al.
Published: (2024-02-01)

The Current Status of the Liver Liquid Biopsy in MASH Related HCC: Overview and Future Directions
by: Onyinye Ugonabo, et al.
Published: (2023-09-01)

Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH
by: Quentin M. Anstee, et al.
Published: (2024-04-01)

The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis
by: Yvonne Burmeister, et al.
Published: (2023-12-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
by: Katharina Staufer, et al.
Published: (2023-07-01)

New stirrer for mash copper.
by: I. SENGE
Published: (2002-05-01)

NAFLD: Mechanisms, Treatments, and Biomarkers
by: Fatiha Nassir
Published: (2022-06-01)

Technological aspects of infusion and decoction mashing.
by: Jan ENGE, et al.
Published: (2005-05-01)

Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice
by: Carlos Cuño-Gómiz, et al.
Published: (2023-11-01)

A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study
by: Qiling Liu, et al.
Published: (2022-11-01)

The role of lymphatic endothelial cells in liver injury and tumor development
by: Veronika Lukacs-Kornek
Published: (2016-11-01)

The potato chips and dry mashed as products of potato rational processing
by: A. Mazur
Published: (2015-05-01)

Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
by: Byeong Geun Song, et al.
Published: (2024-03-01)

TNFα is a key trigger of inflammation in diet-induced non-obese MASLD in mice
by: Katharina Burger, et al.
Published: (2023-10-01)

Rheological behavior of Senga Sengana strawberry mash
by: Bukurov Maša, et al.
Published: (2012-01-01)

Metabolic Dysfunction-Associated Fatty Liver Disease in the National Health and Nutrition Examination Survey 2017–2020: Epidemiology, Clinical Correlates, and the Role of Diagnostic Scores
by: Panagiotis Theofilis, et al.
Published: (2022-11-01)

Unraveling the Connection between Fatty Liver Severity with Gender, Lifestyle, and Health Risks among Workers
by: Feng-Cheng Tang, et al.
Published: (2023-11-01)

The complex myeloid network of the liver with diverse functional capacity at steady state and in inflammation
by: Christoph eEckert, et al.
Published: (2015-04-01)

From MASH to HCC: the role of Gas6/TAM receptors
by: Daria Apostolo, et al.
Published: (2024-01-01)

Role of the co-stimulatory molecule inducible T-cell co-stimulator ligand (ICOSL) in the progression of experimental metabolic dysfunction-associated steatohepatitis
by: Alessia Provera, et al.
Published: (2023-11-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
by: Wayne Eskridge, et al.
Published: (2023-09-01)

The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
by: Ziyan Feng, et al.
Published: (2024-03-01)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
by: Gi-Ae Kim, et al.
Published: (2023-10-01)

Validation of the Hepamet fibrosis score in a multi-ethnic Asian population
by: Shi-En Chong, et al.
Published: (2023-03-01)

What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
by: Giovanni Targher
Published: (2020-10-01)

Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations
by: Anton Gillessen, MD, et al.
Published: (2022-01-01)

The Potential Role of C-Reactive Protein in Metabolic-Dysfunction-Associated Fatty Liver Disease and Aging
by: Zheng Ding, et al.
Published: (2023-10-01)

Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort
by: Yao-Wei Zou, et al.
Published: (2022-05-01)

Pediatric vs. adult NAFLD to MAFLD transition: a welcome but tangled path
by: Angelo Colucci, et al.
Published: (2021-08-01)

Prevalencia de la esteatosis hepática metabólica (EHMet) en pacientes con litiasis vesicular. Estudio de una cohorte de casos en el sur-sureste de México
by: F. Roesch-Dietlen, et al.
Published: (2023-07-01)

Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis
by: Christian Stoess, et al.
Published: (2023-08-01)

Analysis of using brewery mash for energy
by: Z Konrád, et al.
Published: (2014-03-01)

Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
by: Anna Stefanska, et al.
Published: (2024-01-01)

Association of Serum Vitamin C With NAFLD and MAFLD Among Adults in the United States
by: Zhi-Qin Xie, et al.
Published: (2022-02-01)

Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis
by: Beatrice Foglia, et al.
Published: (2024-02-01)

Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
by: Yu Jia, et al.
Published: (2023-10-01)

Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease
by: Juan Moreno-Vedia, et al.
Published: (2022-01-01)

Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics
by: Gary Huang, et al.
Published: (2023-10-01)

Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease
by: A. Lum Han, et al.
Published: (2022-07-01)